All sponsors

Corcept Therapeutics $CORT

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING3
READOUTS ≤12 MONTHS2
Open Corcept Therapeutics on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Relacorilant 150 mg
NCT05257408
P3Active, not recruitingOvarian Neoplasm; Fallopian Tube Neoplasms3812025-03-31 (+10 mo)
Nenocorilant 200 mg
NCT07276373
P1/2RecruitingNeoplasms502026-09
DAZALS
NCT05407324
P2Active, not recruitingAmyotrophic Lateral Sclerosis2792026-10 (+29 mo)
relacorilant
NCT03604198
P2Active, not recruitingCushing Syndrome1252026-12 (+65 mo)
Relacorilant
NCT07259317
P2RecruitingAdenocarcinoma; Carcinoma, Pancreatic Ductal802027-09
Relacorilant 150 mg once daily (QD)
NCT06906341
P2RecruitingOvarian Cancer; Fallopian Tube Cancer2702027-12 (+16 mo)